Ronald Plasterk introduces us to his new company, Tzu Cancer Therapeutics, and the importance of focusing on circulating tumor cells
After selling his previous company, Frame Therapeutics, to CureVac, the Amsterdam based molecular biologist and entrepreneur wants to better translate the knowledge that can be derived from circulating tumor cells into therapies.